National Patient Group Directions and Medicines Policies
Released in 2016 the first Carter report set the scene for improving both efficiency and productivity across NHS acute hospitals; in May 2018 the second Carter report was published. This second report makes a recommendation (Recommendation 11) to improve both efficiency and productivity in the NHS by standardising the development and distribution of PGDs, medicines policies and other essential organisational governance documents across NHS organisations with the aim of releasing significant local resource to be redeployed on optimising outcomes from medicines use.
SPS have established the Medicines Governance Do Once (MGDO) Secretariat. This Secretariat provides the oversight for the ‘Do Once’ project; its members are from SPS Medicines Use and Safety team (MUS), NHS Improvement and NHS England. It is this group who will ensure the programme is delivered with oversight and support from the Regional Medicines Optimisation Committees (RMOCs).
What are the benefits to organisations?
- Consistency, quality and reduced variability
- Alignment with national guidance
- Increased organisational capacity releasing local resources to work within other medicines optimisation areas
Who is this information for?
We want all NHS services where medicines are used to know about the Medicines Governance Do Once Programme. We are therefore providing current information and transparency on the development and publication of national medicines governance documentation.
The MGDO Secretariat has developed a system to produce PGDs and guidance documents.
PGDs will be developed in Short Life Working Groups (SLWGs) which will include Subject Matter Experts (SMEs). SMEs will be recognised leaders working in the clinical environment where the PGDs will be used. Further details on the process can be found below. Our PGD work plan is shared below.
The proposal paper submitted to the RMOC, the MGDO Secretariat Terms of Reference, the Governance Structure, the MGDO PGD process, and a Position Paper written in January 2019 can all be accessed below.
March 2020 update – due to current system pressures we have moved to developing template PGDs. These templates will require organisations to locally provide clinical and organisational sign off. The templates have been developed with SMEs and the relevant national clinical body has approved them. These template PGDs can be found by following the links below (see Links section below).
PGDs are not always required. We have produced guidance on when PGDs should not be used and advice on alternative mechanisms for supply and administration of medicines. Link
At the request of a number of organisations, we have published the PGD template that we are using when developing the national PGDs. Link